At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
sorafenibdrug
Likely dose
sorafenib 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Efficacy and Tolerability of the Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
In Brief
A Phase 2 clinical trial evaluating sorafenib for Renal Cell Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether an increase in the dose of sorafenib when given over five instead of 7 days/week, will result in an improvement of the response rate (degree of shrinkage of your cancer) and an improvement in the length of time that sorafenib will control your cancer, without causing a significant increase in side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Cancer
CountriesUnited States
CollaboratorsBayer
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedAug 2010
Primary CompletionApr 2015
TodayJul 2026
First PostedAug 26, 2010
Enrollment StartJun 1, 2008
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 15.8 years ago
Interventions
sorafenibdrug
Dose Level: 1. 400mg twice daily, continuous. 2. 600mg twice daily, days 1-5 of each week. 3. 800mg twice daily, days 1-5 of each week.